The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

The medication lecanemab was approved by the U.S. FDA to treat Alzheimer’s disease in 2023. Like all medications, lecanemab comes with the potential for side effects, including amyloid-related imaging ...

STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an ...

Last year, the National Institute of Health and Care Excellence (Nice) rejected the NHS rollout of the first two drugs – lecanemab and donanemab – that were found to halt the progression of disease.

Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, ...

Canada’s public drug plans should not pay for a new medication that slows cognitive decline in Alzheimer’s patients because it’s not clear the expensive therapy provides clinically meaningful benefits ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes, living independently, for longer periods of time. Those medications, while effective, are not without ...

Alzheimer's Research UK's response to Baroness Casey of Blackstock calling on the Government to act now to tackle the ...